Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of **Danlou tablet**, **Salvia miltiorrhiza** (Danshen), and **ligustrazine** (tetramethylpyrazine) is a therapeutic regimen used in Traditional Chinese Medicine (TCM) for the treatment of cardiovascular conditions, specifically **chronic stable angina**. Danlou tablet is a standardized Chinese patent medicine composed of ten herbs (including *Trichosanthes kirilowii*, *Allium macrostemon*, and *Pueraria lobata*) designed to resolve phlegm, remove blood stasis, and unblock the collaterals. Salvia miltiorrhiza and ligustrazine (often administered together as a fixed-dose injection) provide potent synergistic effects by promoting blood circulation, inhibiting platelet aggregation, and inducing vasodilation. This combination therapy targets the 'phlegm-stasis' pathogenesis common in coronary heart disease, aiming to improve myocardial blood supply, reduce inflammatory markers like C-reactive protein and NF-kappa B, and alleviate anginal symptoms. The regimen has been studied and utilized by institutions such as the **Traditional Chinese Medicine Hospital of Tailai County** to enhance clinical outcomes in patients with stable coronary artery disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danlou tablet + salvia miltiorrhiza + ligustrazine.